Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of “Buy” by Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned an average rating of “Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $6.63.

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Monday, January 6th. Finally, JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th.

Taysha Gene Therapies Trading Down 0.7 %

NASDAQ:TSHA opened at $1.52 on Monday. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm’s fifty day moving average is $2.08 and its 200-day moving average is $2.08. The firm has a market cap of $311.51 million, a P/E ratio of 2.41 and a beta of 0.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at $1,018,000. Rhumbline Advisers bought a new position in Taysha Gene Therapies during the second quarter valued at about $413,000. The Manufacturers Life Insurance Company grew its position in Taysha Gene Therapies by 109.0% during the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after buying an additional 69,487 shares during the period. Scientech Research LLC purchased a new stake in Taysha Gene Therapies during the second quarter worth about $97,000. Finally, SG Americas Securities LLC bought a new stake in Taysha Gene Therapies in the third quarter worth about $129,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.